Stronger Q2 Results And Higher Potash Guidance Might Change The Case For Investing In Nutrien (TSX:NTR)

• Nutrien Ltd. reported second-quarter 2026 results with sales of US$10,812 million and net income of US$1,214 million, and its board declared a quarterly dividend of US$0.55 per share payable on October 16, 2026.
• Alongside earnings, Nutrien raised its 2026 potash sales volume guidance and highlighted reliability-driven volume expectations in nitrogen and phosphate, while completing a US$261 million share buyback of 3,732,920 shares.
• We’ll now examine how the upgraded potash sales volume guidance and operational improvements influence Nutrien’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Nutrien Investment Narrative Recap

To own Nutrien, you need to believe fertilizer will remain essential to global food production and that the company can keep translating that into solid cash generation. The latest results and modest upgrade to potash volume guidance support this core view but do not fundamentally change the near term picture. The key catalyst still lies in how efficiently Nutrien runs its potash and nitrogen assets, while the biggest current risk remains mounting environmental and regulatory pressures on fertilizer production.

The most relevant update here is Nutrien’s higher 2026 potash sales volume guidance of 14.2 million to 14.8 million tonnes, supported by strong offshore demand. Together with reliability driven expectations in nitrogen and phosphate, this ties directly into the operational improvement catalyst that many investors focus on: squeezing more volume out of existing assets. These efficiency gains could matter more for the story than the steady US$0.55 dividend or the US$261 million buyback in the short term.

Yet while volumes are moving in the right direction, investors should also be aware that tightening environmental regulations could...

Read the full narrative on Nutrien (it's free!)

Nutrien's narrative projects $27.3 billion revenue and $2.2 billion earnings by 2029. This implies flat yearly revenue and a $0.2 billion earnings decrease from $2.4 billion today.

Uncover how Nutrien's forecasts yield a CA$110.93 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a far more cautious view, expecting earnings to fall toward about US$1.7 billion on flat revenue, so if you are weighing Nutrien’s stronger 2026 volume guidance against that more pessimistic backdrop, it is worth exploring how much faith you place in cost savings and efficiency gains to offset tougher regulatory and competitive pressures.

Explore 5 other fair value estimates on Nutrien - why the stock might be worth just CA$97.46!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nutrien research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Nutrien research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nutrien's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 4 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 10 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com